See more : LivePerson, Inc. (LPSN) Income Statement Analysis – Financial Results
Complete financial analysis of Marrone Bio Innovations, Inc. (MBII) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Marrone Bio Innovations, Inc., a leading company in the Agricultural Inputs industry within the Basic Materials sector.
- Falanx Cyber Security Limited (FCS.L) Income Statement Analysis – Financial Results
- Chandra Bhagat Pharma Limited (CBPL.BO) Income Statement Analysis – Financial Results
- Ryvu Therapeutics S.A. (RVU.WA) Income Statement Analysis – Financial Results
- The Travelers Companies, Inc. (PA9.DE) Income Statement Analysis – Financial Results
- Zhejiang Garden Bio-chemical High-tech Co., Ltd. (300401.SZ) Income Statement Analysis – Financial Results
Marrone Bio Innovations, Inc. (MBII)
About Marrone Bio Innovations, Inc.
Marrone Bio Innovations, Inc. discovers, develops, and sells biological products for crop protection, crop health, and crop nutrition. Its products include Emergen, Foramin, Foramin ST, Optima, Takla, Pacesetter, Ympact, UBP, and UBP ST for increasing crop health, yield, and quality; Grandevo, a bioinsecticide that controls sucking and chewing insects through feeding; Haven, a plant health product to reduce sun stress and dehydration; Jet-Ag and Jet-Oxide peroxyacetic acid sanitizers that prevent, suppress, eliminate, and control algae, fungi, and bacterial diseases in agriculture and horticultural industries; and Majestene, a bionematicide to control soil-dwelling nematodes and certain soil borne insects. The company also offers Regalia and Stargus, which protects against fungal and bacterial diseases and enhances yields/quality; Venerate, a bioinsecticide that controls chewing and sucking insects and mites; and Zelto, a bionematicide that protects turf, including golf course fairways and greens, and promotes turf health by enhancing plant and root health. It provides its products directly through sales force, as well as through distributors and other commercial partners. The company formerly known as Marrone Organic Innovations, Inc. Marrone Bio Innovations, Inc. was incorporated in 2006 and is headquartered in Raleigh, North Carolina.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 44.31M | 100.00K | 29.37M | 21.22M | 18.17M | 14.04M | 9.80M | 9.14M | 14.54M | 7.14M | 5.25M |
| Cost of Revenue | 17.06M | 40.00K | 13.26M | 10.91M | 10.53M | 9.52M | 9.26M | 9.44M | 10.74M | 4.33M | 2.17M |
| Gross Profit | 27.25M | 60.00K | 16.11M | 10.31M | 7.64M | 4.52M | 545.00K | -302.00K | 3.81M | 2.81M | 3.08M |
| Gross Profit Ratio | 61.49% | 60.00% | 54.86% | 48.60% | 42.05% | 32.19% | 5.56% | -3.31% | 26.18% | 39.31% | 58.64% |
| Research & Development | 12.08M | 30.00K | 14.03M | 10.66M | 10.82M | 9.67M | 13.50M | 19.28M | 17.81M | 12.74M | 9.41M |
| General & Administrative | 0.00 | 75.00K | 30.07M | 19.16M | 19.81M | 18.51M | 26.50M | 28.95M | 15.02M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 30.57M | 75.00K | 30.07M | 19.16M | 19.81M | 18.51M | 26.50M | 28.95M | 15.02M | 0.00 | 0.00 |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.29M | 6.79M |
| Operating Expenses | 42.65M | 105.00K | 44.10M | 29.82M | 30.63M | 28.18M | 40.00M | 48.23M | 32.83M | 23.04M | 16.20M |
| Cost & Expenses | 59.71M | 145.00K | 57.36M | 40.72M | 41.16M | 37.70M | 49.26M | 57.67M | 43.57M | 27.37M | 18.38M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 1.00K | 37.00K | 51.00K | 59.00K | 49.00K | 16.00K | 22.00K |
| Interest Expense | 1.57M | 4.00K | 1.47M | 2.51M | 7.73M | 7.30M | 4.36M | 2.91M | 6.00M | 2.47M | 88.00K |
| Depreciation & Amortization | 4.57M | 3.56M | 3.15M | 1.89M | 2.04M | 2.24M | 3.51M | 2.58M | 976.00K | 613.00K | 499.00K |
| EBITDA | -10.37M | 3.51M | -32.53M | -15.82M | -21.15M | -21.53M | -35.86M | -46.17M | -21.52M | -35.72M | -12.59M |
| EBITDA Ratio | -23.41% | 3,509.00% | -110.75% | -74.53% | -116.43% | -153.35% | -365.83% | -505.37% | -147.95% | -500.21% | -239.82% |
| Operating Income | -14.94M | -17.20M | -27.99M | -19.50M | -23.00M | -23.66M | -39.46M | -48.53M | -29.03M | -23.84M | -13.12M |
| Operating Income Ratio | -33.71% | -17,195.00% | -95.27% | -91.91% | -126.58% | -168.49% | -402.58% | -531.23% | -199.58% | -333.87% | -249.93% |
| Total Other Income/Expenses | -1.57M | 17.14M | -9.19M | -709.00K | -7.93M | -7.41M | -4.27M | -3.13M | 536.00K | -14.96M | -56.00K |
| Income Before Tax | -16.51M | -53.00K | -37.18M | -20.21M | -30.93M | -31.07M | -43.73M | -51.66M | -28.49M | -38.79M | -13.18M |
| Income Before Tax Ratio | -37.26% | -53.00% | -126.56% | -95.25% | -170.23% | -221.27% | -446.16% | -565.44% | -195.89% | -543.33% | -251.00% |
| Income Tax Expense | 45.00K | 17.15M | 15.00K | 1.80M | -201.00K | -109.00K | 92.00K | -219.00K | 6.53M | -12.49M | 32.00K |
| Net Income | -16.55M | -53.00K | -37.18M | -20.21M | -30.93M | -31.07M | -43.73M | -51.66M | -28.49M | -38.79M | -13.18M |
| Net Income Ratio | -37.36% | -53.00% | -126.56% | -95.25% | -170.23% | -221.27% | -446.16% | -565.44% | -195.89% | -543.33% | -251.00% |
| EPS | -0.09 | 0.00 | -0.32 | -0.20 | -1.06 | -1.26 | -1.79 | -2.32 | -3.26 | -2.12 | -0.72 |
| EPS Diluted | -0.09 | 0.00 | -0.32 | -0.20 | -1.06 | -1.26 | -1.79 | -2.32 | -3.20 | -2.12 | -0.72 |
| Weighted Avg Shares Out | 174.83M | 148.89M | 117.98M | 101.25M | 29.24M | 24.62M | 24.47M | 22.31M | 8.73M | 18.27M | 18.27M |
| Weighted Avg Shares Out (Dil) | 174.83M | 148.89M | 117.98M | 101.25M | 29.24M | 24.62M | 24.47M | 22.31M | 8.91M | 18.27M | 18.27M |
Marrone Bio Innovations to Report Fourth Quarter and Full Year 2021 Results on Monday, March 28 at 4:30 p.m. Eastern Time
Marrone Bio Announces CFO Transition
Marrone Bio Innovations Issues Shareholder Letter
Marrone (MBII) Expands the Existing Inventory Line of Credit
Marrone Bio's Inventory Line of Credit Increased to Support Sales and Manufacturing Growth
Marrone Bio Relocates Corporate Headquarters to Raleigh, North Carolina
Marrone Bio Warrant Holders Exercise Final Tranche, Eliminating Warrant Overhang
Marrone Bio's Next-Generation Product for Environmentally Sustainable Pest Control Demonstrates Substantial Yield Gains in 2021 Field Trials
Switching From Israel Chemicals To Mosaic
Marrone Bio Achieves Excellent Climate Impact Score for Venerate® XC Bioinsecticide
Source: https://incomestatements.info
Category: Stock Reports